Ascentage Pharma Group International Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist

This Ascentage Pharma Group International Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP establishes pipeline ownership and stage, reconstructs transaction precedents and surfaces financial signals; Current Awareness MCP adds recent events and outreach clues. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions where returned. This is a screening memorandum, not legal, medical, patent or investment advice.

Executive BD screen

Ascentage Pharma Group International returned 35 pipeline records in the organization search. The near-term screen centers on Lisaftoclax, reported at Approved, with ownership attributed to Suzhou Yasheng Pharmaceutical Co., Ltd.; Ascentage Pharma Group, Inc.; Ascentage Pharma Group International Co., Ltd.. The Ascentage Pharma Group International organization website was checked as an external organization reference; ownership still requires confirmation against current corporate and asset records.

The practical partnering thesis is to qualify the current owner, validate the evidence package behind the next development milestone, and determine whether geography, indication, combination, manufacturing or option rights remain available. The shortlist below is prioritized by returned maturity rather than an unverified probability-of-success score.

Partnering shortlist

Owner caution: returned owner names include Suzhou Yasheng Pharmaceutical Co., Ltd.; Ascentage Pharma Group, Inc.; Ascentage Pharma Group International Co., Ltd.; Guangzhou Shunjian Biomedical Technology Co. Ltd.. Confirm legal entity, chain of title, encumbrances and sublicensing authority before relying on the owner field.

Evidence package to request

• Clinical: protocol, statistical analysis plan, patient-level disposition, efficacy tables, safety narratives, biomarker plan and regulator correspondence for Lisaftoclax.
• Translational: target engagement, dose–exposure–response, model relevance, resistance hypotheses and differentiation versus current standard of care.
• CMC: process description, specifications, comparability history, stability, scale-up assumptions, critical suppliers and cost-of-goods model.
• Commercial: target product profile, addressable segments, competitive trials, pricing/access assumptions and regional launch requirements.
• Corporate: cap table, program budget, existing alliances, change-of-control terms and a complete schedule of third-party obligations.

IP and freedom-to-operate risk

Map composition-of-matter, target-mechanism, formulation and use claims around Bcl-2; confirm assignments and territory coverage. The scan does not substitute for claim-chart analysis. Diligence should reconcile patent-family ownership, inventorship, priority support, prosecution status, expiry and patent-term adjustment, licenses, government funding, employee/consultant assignments, oppositions and litigation. Separate platform blocking risk from asset-specific composition, use, dosing, formulation and manufacturing risk.

Deal precedent and transaction framing

• 亚盛医药与多家医药流通龙头企业达成合作，全面推进利生妥®商业化布局 (2025-07-22). Economics were not disclosed in the returned record.
• 亚盛医药集团与Takeda International订立独家选择权协议 (2024-06-14). Disclosed economics include US$100 million upfront and US$1200 million in milestones.
• Ascentage Pharma and NCI will collaborate in a CRADA for the non-clinical and clinical development of pelcitoclax for solid tumors. (2021-07-19). Economics were not disclosed in the returned record.

Use returned transactions as negotiation anchors only after normalizing modality, stage at signing, territory, option structure, cost sharing and development obligations. Where no directly comparable precedent is returned, construct a broader target-, modality- and indication-level set before proposing economics.

Financial signals

• Ascentage Pharma Group International - 财务资料: Ascentage Pharma Group International - 财务资料 概览 本文件为草拟本，其所载资料并不完整及可作更改。阅读本文件所载资料时，须一并细阅 本文件首页「警告」一节。 于往绩记录期，我们并无自销售本公司产品产生任何收益，仅确认了有限的通过向客 户提供非经常性的研发服务以及知识产权许可费而获取的收入。作为专注于创新的生物科 技公司，我们于往绩记录期产生大量研发开支。为研发我们的候选药物，截至2016 年、 2017 年及2018 年12 月31 日止年度，我们在候选药物的研发方面分别录得研发费用人民币 102.7 百万元、人民币118.8 百万元及人民币249.6 百万元。于2016 年、2017 年及2018 年， 我们分别录得亏损净额人民币107.8…
• Ascentage Pharma Group International - 未来计划及[ 编纂]: Ascentage Pharma Group International - 未来计划及[ 编纂] 未来计划及[ 编纂] 倘[ 编纂] 获悉数行使，本公司将收取的额外[ 编纂] 净额将约为[ 编纂] 港元，假设[ 编 纂] 为每股股份[ 编纂] 港元（即建议[ 编纂] 范围的中位数）。本公司或须根据[ 编纂] 发行合 共不多于[ 编纂] 股额外股份。 倘[ 编纂][ 编纂] 净额并无即时为上述用途所需或倘我们未能如预期般落实发展计划的 任何部分，倘以短期存款持有该等资金视作符合本公司的最佳利益，则我们或以该方式持 有该等资金。在有关情况下，我们将遵守上市规则的适当披露规定。 本文件为草拟本，其所载资料并不完整及可作更改。阅读本文件所载资料时，须一并细阅 本文件首页「警告」一节。 我们或会将此项[ 编纂]…

Financial-report passages are outreach signals rather than a valuation model. Translate them into questions about runway, program prioritization, non-dilutive capital needs, development-cost sharing and willingness to trade territory for funding or capabilities.

Recent events and timing clues

• No recent company-specific news passage was returned. Confirm material events, trial changes, financing and partnering activity through current disclosures.

Reconfirm every time-sensitive event before contact. The strongest outreach window is normally just before a financing, data readout, regulator interaction, indication expansion or manufacturing commitment—when a partner can change the risk or capital profile.

Recommended outreach sequence

1. Confirm ownership: contact business development and legal with a one-page statement of interest naming Lisaftoclax, territory and proposed collaboration type.
2. Request a staged data room: begin with non-confidential evidence, then gate patient-level, CMC and IP materials under NDA.
3. Offer a specific value exchange: link capital, development execution, regulatory access, manufacturing or commercialization reach to the owner’s next milestone.
4. Propose structure: compare regional license, option-to-license, co-development and asset acquisition pathways with explicit decision points.
5. Define stop/go criteria: ownership defects, unsupported differentiation, unmanageable safety/CMC risk or blocking IP should pause valuation work.

Decision gates for the partnering team

Advance the opportunity only when four gates can be answered with traceable evidence. First, the legal owner must control the asset and the rights under discussion. Second, the next development milestone must be supported by a coherent clinical, translational and CMC package. Third, the proposed partner must contribute a capability that changes probability, timing, cost or commercial reach rather than merely adding capital. Fourth, the transaction must remain attractive after probability adjustment, remaining development spend, competitive displacement and third-party obligations.

At the initial screen, classify each gate as supported, unresolved or adverse. Unresolved items become dated data-room requests with a named owner; adverse items require a mitigation plan and explicit valuation effect. This discipline keeps early enthusiasm from turning missing evidence into an implicit positive assumption and gives both parties a clear path from introductory outreach to diligence, governance design and executable economics.

BD conclusion

Ascentage Pharma Group International merits a targeted, evidence-gated outreach centered on Lisaftoclax and its reported Approved status. The initial objective is not to negotiate headline economics; it is to resolve current ownership, evidence readiness, strategic fit and rights availability. A successful first interaction should produce a clean owner map, milestone calendar, diligence index and agreed pathway to a term-sheet discussion.

Build your next partnering scan with PatSnap MCP. Connect pipeline, transaction, financial and current-awareness evidence through the PatSnap MCP server marketplace.